You are here
Practical management of advanced mCRPC
Professor Nicolas Mottet, Université Jean Monnet, St. Etienne, presents the case of a 62 years old patient with moderately differentiated adenocarcinoma of the prostate (Gleason 7) treated by radical prostatectomy. Two years he relapsed and goserelin and bicalutamide was offered. Following progression he was treated with docetaxel and prednisolone (6 cycles). After a short response PSA level raised to 66 ng/ml and back pain and bone metastases were present. The question is how to treat this patient with progressive mCRPC: docetaxel rechallenge, cabazitaxel, abiraterone plus prednisone, enzalutamide or radium-223?